Segui questo link per vedere altri tipi di pubblicazioni sul tema: AES Sul.
Articoli di riviste sul tema "AES Sul"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "AES Sul".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.
1
Noro, Greice de Bem, Eduardo Botti Abbade e Jackson Oliveira. "O Alinhamento entre os Tipos de Projetos e as Competências Gerenciais nos Projetos da AES Sul Distribuidora Gaúcha de Energia SA". Revista de Gestão e Projetos 2, n. 1 (18 ottobre 2011): 106–42. http://dx.doi.org/10.5585/gep.v2i1.30.
Testo completoAbstract (sommario):
A busca pela excelência e por novos mercados e clientes tem impulsionado as empresas a procurarem por metodologias e formas de alcançarem seus objetivos para aprimorar suas estratégias e vantagens competitivas. Nesse sentido, o gerenciamento de projetos (GP) tem tido um papel fundamental nas organizações para adequar prazos, organizar métodos e tomadas de decisão da forma e na hora certa. Embora muitas empresas já utilizem o GP como forma de alcançar seus objetivos, o presente trabalho intenta aprimorar ainda mais esse gerenciamento ao levantar o debate acerca de alinhar os diversos tipos de projetos das empresas com a escolha adequada do líder, em consonância com suas competências. O trabalho foi desenvolvido na empresa AES Sul Distribuidora Gaúcha de Energia SA (AES Sul) com o objetivo de analisar como o alinhamento dos tipos de projetos às competências gerenciais, que os gerentes de projeto da AES Sul devem ter, pode agregar valor à organização. No que tange aos procedimentos metodológicos, a presente pesquisa classifica-se como quali-quantitativa, descritiva, realizada por meio de um estudo de caso. Como principais resultados evidenciam-se a necessidade de adequações das competências essenciais e básicas aos determinados tipos de projetos da AES Sul e a constatação de alguns gaps em relação às competências de seus líderes.DOI:10.5585/gep.v2i1.30
2
Santos Filho, Gildo Magalhães dos. "Da usina à população na velocidade da luz: fios elétricos e desenvolvimento". Labor e Engenho 9, n. 1 (9 marzo 2015): 6. http://dx.doi.org/10.20396/lobore.v9i1.2090.
Testo completoAbstract (sommario):
O Projeto Eletromemória se destina ao estudo da história da eletri_icação no estado de São Paulo no período de 1890 a 2005. Sua primeira fase transcorreu entre 2007 e 2010, investigando as usinas, a documentação de arquivos e a cultura material das empresas CESP (rios Paraná, Grande e Paráiba do Sul), AES-Tietê (rio Tietê), Duke Energy (rio Paranapanema), bem como as subestações do sistema de transmissão da ISA-CTEEP no interior do estado e as da AES-Eletropaulo na Grande São Paulo. A segunda fase foi iniciada em 2013 e engloba as usinas da EMAE, da CPFL e de algumas pequenas concessionárias, construídas entre 1890 e 1960. O autor discorre também sobre as áreas de pesquisa abrangidas no Projeto - história da tecnologia, patrimônio industrial, museologia, geogra_ia, arquivologia e biblioteconomia - para depois esboçar um breve panorama histórico do processo.
3
Rosa, Iriane, Ivonisa Abreu e Ivonete Pedrozo. "Avaliação da localização do centro de distribuição da empresa AES Sul distribuidora gaúcha de energia em relação aos depósitos regionais". Revista de Administração da UFSM 9, n. 3 (2 ottobre 2016): 356–71. http://dx.doi.org/10.5902/1983465915358.
Testo completoAbstract (sommario):
Companies that provide services basic as distribution of energy electric should keep the continuity of services independent of situation because they are necessary to provide the terms minimal for the life in society. The intention this study is create an analysis on the location of distribution center of materials of concessionaire AES Sul Distribuidora Gaúcha de Energia, today located in city of Esteio, Rio Grande do Sul. Was evaluated what the place, within of his field of concession, can attend the deposits regional with higher quality. This review becomes necessary, because the delay for the delivery the materials used in its units regional back delays in recovery of network of distribution of energy electric or lag in attendance of new installation both residential as industrial. For this review are related them variables of consumption and time of attend through of methodologies of center of gravity and of units of emergencies. After the enforcement of methodology proved that the region central of his area of concession is the region more adequate for de mounting of his units of distribution of materials.
4
Farenzena, Nalú, Caroline Cristiano Cardoso e Cleusa Conceição Terres Schuch. "Uma análise da formulação do Sistema Estadual de Avaliação Participativa do Rio Grande do Sul". Dialogia, n. 22 (6 novembre 2015): 87–101. http://dx.doi.org/10.5585/dialogia.n22.5981.
Testo completoAbstract (sommario):
O artigo tem como objetivo analisar significados atribudos ao Sistema Estadual de Avaliao Participativa na sua fase inicial de formulao, nos anos de 2011 e 2012. empregada metodologia de anlise de formulao de poltica pblica e os dados empricos provm de documentos e de entrevistas realizadas com os principais atores da formulao. A partir do exame da colocao da poltica na agenda governamental e de contedos referentes s suas motivaes e finalidades, evidenciado que o Seap reuniu anseios de proposio de um sistema alternativo s avaliaes de larga escala de estudantes, de obteno de dados de contexto complementares para a (re)formulao de aes pblicas e de promoo da democratizao nas instncias escolares e administrativas da rede estadual de educao.
5
Mello, Simone Portella Teixeira de, Pedro Antônio de Melo e Raul Teixeira de Mello Filho. "Estudando a evasão no ensino tecnológico em uma instituição de ensino superior no sul do Brasil". EccoS – Revista Científica, n. 37 (12 gennaio 2015): 181–96. http://dx.doi.org/10.5585/eccos.n37.4890.
Testo completoAbstract (sommario):
A evaso fenmeno complexo que acontece no espao pblico e privado. Este estudo apresenta o perfil do evadido dos cursos superiores de tecnologia de uma universidade no sul do Brasil, os motivos de desistncia e alternativas de permanncia. Fez-se reviso bibliogrfica em artigos em peridicos Qualis, entrevistas com evadidos utilizando-se software Lime Survey. Os resultados revelam que homens evadem mais que mulheres, 66,67% tm entre 20 e 29 anos. O motivo mais frequente a troca de curso na IES seguido de ingresso em outra. Sentimentos de perda dos alunos levam a um compromisso maior da universidade: executar de fato o prescrito nos projetos pedaggicos dos cursos. Dilogo essencial para que o aluno no desista e caminhos para isso podem ser: criao de rede de relacionamentos virtual, aes psicopedaggicas, maior flexibilidade curricular e bolsas de permanncia. O sentimento de pertencimento deve ser estimulado no ensino superior brasileiro.
6
Moreira, Hilton Lenzi, e Virlei Álvaro de Oliveira. "Evolução e gênese de um Plintossolo Pétrico concrecionário êutrico argissólico no município de Ouro Verde de Goiás". Revista Brasileira de Ciência do Solo 32, n. 4 (agosto 2008): 1683–90. http://dx.doi.org/10.1590/s0100-06832008000400033.
Testo completoAbstract (sommario):
Solos concrecionários (Plintossolo Pétrico concrecionário) nas Regiões Central e Norte do Brasil são muito comuns, ocorrendo em áreas baixas e nas bordas das chapadas, constituindo geralmente solos distróficos,pobres em nutrientes. A ocorrência de solo concrecionário eutrófico no município de Ouro Verde de Goiás, em área de borda de chapada motivou esta pesquisa, desenvolvida com a finalidade de verificar a relação eutrofia/solo/material litológico subjacente, provável fonte das bases trocáveis. As relações pedológicas e geoquímicas do solo com as concreções e a rocha de origem foram pesquisadas por meio de determinações da constituição química total dos elementos maiores, utilizando ICP-AES (espectrometria de emissão atômica por plasma acoplado indutivamente), análise mineralógica da fração argila por DRX, análise mineralógica da fração areia, além da caracterização analítica de rotina em pedologia. Os resultados analíticos de amostras de rocha, concreções ferruginosas e TFSA, as relações moleculares Ki e Kr e bases/R2O3 e a relação Zr/Ti são abordados e discutidos. Ocorrências mais significativas quanto a alguns elementos móveis são creditadas ao conteúdo elevado de matéria orgânica no horizonte superficial do solo, ao acúmulo residual de quartzo e à contribuição de material externo nos horizontes superiores . A relação solo/material litológico subjacente indica para o perfil de origem a partir de um metatonalito, atribuindo-se ao material petroplíntico presente na porção superior do solo, origem relacionada à desagregação e arraste de materiais relacionados à Superfície de Aplanamento Sul-Americana.
7
Keaney, A., e J. F. Alder. "Mechanistic Study of the Effect of Sulphur Dioxide and Nitrogen Dioxide Exposure of ASC/T, Whetlerised BPL and Whetlerised Chlorinated BPL Activated Carbons on the Chemisorption of Hydrogen Cyanide from Air". Adsorption Science & Technology 16, n. 2 (marzo 1998): 101–15. http://dx.doi.org/10.1177/026361749801600204.
Testo completoAbstract (sommario):
Three activated carbons, ASC/T, Whetlerised BPL and Whetlerised chlorinated BPL (BPL/C) (4.5 %w/w chlorine/carbon) were tested extensively on their adsorption behaviour towards HCN in air, before and after exposure to SO2 and NO2 in air at pressures from 2 to 500 mbar. Whetlerite impregnation solutions of carefully controlled compositions were made up to treat the BPL and BPL/C. ASC/T and the resulting Whetlerised carbons BPL/W and BPL/WC were examined. Nitrogen isotherm data were obtained for these carbons before and after exposure to SO2 and NO2. The carbons were also analysed by ICP-AES and AAS for total Cr, and by alkaline extraction then spectrophotometric analysis using diphenylcarbazide reagent, for the determination of CrVI. The ASC/T, BPL/W and BPL/WC were challenged by 2 mg/l HCN in air at 22°C/80% relative humidity (RH) before and after exposure to SO2 and NO2. Surface area, microporous volume N2 adsorption energy and pore size distribution data were obtained for the range of carbons from the nitrogen isotherms. Adsorption rate constants, adsorption capacity and adsorption site densities for HCN and (CN)2 were obtained. Analysis of the results for all three carbons shows that the principal effects of SO2 and NO2 are in reducing the fraction of Cr as CrVI and in blocking the micropore adsorption sites for HCN and (CN)2. There is little obvious correlation between SO2 or NO2 loading and the N2 adsorption rate constants and N2 adsorption energies. There is an overall reduction in microporous area and volume on exposure of ASC/T to both SO2 and, to a lesser but still marked degree, to NO2. The biggest reduction is in the fraction of pores <5 Å radius. It is thought that the reduction in breakthrough time and the related adsorption capacity for HCN and (CN)2 is due to chemical reduction of the CrVI by SO2 on the carbons giving sulphate or sul-phuric acid species, both blocking the microporous structure and reducing the ability of CrVI to oxidise the copper cyanide complexes to oxamide. Analogous mechanisms are proposed to explain the lesser but nonetheless marked effect of NO2 exposure. These findings are consistent with earlier work in the authors' laboratory and that reported elsewhere.
8
Banger, Markus, Michael Specka, Ernst Lodemann, Thomas Finkbeiner, Clemens Rösinger e Sven-Uwe Kutscher. "Entwicklung einer Selbstbeurteilungsskala für das Alkoholentzugssyndrom (ESA, Essener Selbstbeurteilung Alkoholentzugssyndrom)". SUCHT 47, n. 6 (gennaio 2001): 404–13. http://dx.doi.org/10.1024/suc.2001.47.6.404.
Testo completoAbstract (sommario):
Ziel: Die subjektive Seite des Befindens und der Beschwerden der Patienten während des akuten Alkoholentzugssyndroms (AES) blieb bei dessen Therapieevaluation bislang unberücksichtigt. Vorgestellt wird die Entwicklung einer Selbstbeurteilungs-Skala für das AES. </P><P>
Methodik: Eine 28-Item-Version wurde
einer klassischen testtheoretischen Analyse unterzogen. 103 Patienten mit einem akuten AES bei chronischer
Alkoholabhängigkeit wurden in die Untersuchung aufgenommen. </P><P> Ergebnisse: Nach Berechnung von Schwierigkeit, Trennschärfe und interner Konsistenz erfolgte eine Item-Reduktion der Skala. Die Faktorenanalyse der 21-Item-Lösung zeigt nach Varimax-Rotation
eine 1-Faktorlösung. Dabei liegt eine hohe interne Konsistenz vor (Cronbachs alpha = 0.93). Bei einer erneut nach einer Woche gemessenen Subgruppe
der Entzugspatienten (n = 54) zeigte sich eine gute Änderungssensitivität. Zur Validitätsüberprüfung erfolgte ein Vergleich mit abstinenten Alkoholabhängigen und Angstpatienten. </P><P>
Schlussfolgerungen: Es konnte zuverlässig zwischen den Patienten mit einem AES und den abstinenten Patienten unterschieden werden, nicht aber zwischen der Entzugs- und der
Angststichprobe. Die 21-Item-Version des Fragebogens könnte als Instrument zur Qualitätssicherung für den Alkoholentzug eingeführt werden.
9
KATO, Kazuhiro, Fuyuki TOKANAI, Minoru ANSHITA e Hirohisa SAKURAI. "Automatic Sample Combustion and CO2 Collection System for AMS-14C". RADIOISOTOPES 61, n. 9 (2012): 469–73. http://dx.doi.org/10.3769/radioisotopes.61.469.
Testo completo
10
Rodrigues, Vanessa Gehm, Everson Dal Piva, Franciano Scremin Puhales e Vagner Anabor. "Synoptic patterns for days with intense atmospheric electrical activity from 2013 to 2015". Ciência e Natura 40 (11 maggio 2018): 45. http://dx.doi.org/10.5902/2179460x31788.
Testo completoAbstract (sommario):
The following study aimed to analyze data from Atmospheric Electric Discharge (AEDs) from the period between 2013 to 2015, with the objective of obtaining atmospheric patterns for the days with the maximum AED detected near the city of Santa Maria, in the state of Rio Grande do Sul. Data from the Sferics Timing and Ranging NETwork (STARNET) have been used. With a FORTRAN routine, a search at the AED data was performed to obtain the daily maximum of AED in an area of 1 ° per 1 ° centered in the city Santa Maria.One day of each year were found with maximum numbers of AEDs.The gridded atmospheric dataset used to dynamic and thermodynamic analysis were the final analysis from the National Centers for Environmental Prediction (NCEP).The main characteristics found were the proximity of the equatorial entrance of the high-level jet streak and the thermodynamics indices indicating moderate-to-high possibility for storm occurrence. This analysis enabled in the atmospheric characterization associated to events with large daily amount of DEAs and can be used to improve forecast.
11
Middleton, Mark R., Reinhard Dummer, Ralf Gutzmer, Paul Lorigan, Kevin Kim, Marta Nyakas, Ana Maria Arance et al. "Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma." Journal of Clinical Oncology 31, n. 15_suppl (20 maggio 2013): 9004. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9004.
Testo completoAbstract (sommario):
9004 Background: BRAF mutations play an oncogenic role in melanomas. Selumetinib (AZD6244, ARRY-142886) inhibits MEK1/2 downstream of B-Raf and may have an additive effect to chemotherapy. We prospectively evaluated SEL + DTIC vs PBO + DTIC in patients with stage III-IV BRAF mutation-positive advanced cutaneous or unknown primary melanoma (NCT00936221). Methods: Eligible patients (pts) received iv DTIC 1000 mg/m2, and po SEL 75 mg or matched PBO bd as first-line treatment. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety and tolerability. Results: A total of 385 pts were screened across 44 centers; 91 patients were randomized (SEL + DTIC, 45; PBO + DTIC, 46). One pt from each group did not receive the randomized treatment. Baseline characteristics were balanced between the two groups, with the exception of histology, gender and previous medications. At data cut-off, 66 deaths had occurred (73% maturity) and median follow-up was 12.3 mo. OS was longer for SEL + DTIC vs PBO + DTIC (median 13.9 vs 10.5 mo), but this did not meet statistical significance (HR 0.93; 80% CI 0.67, 1.28; 1-sided p=0.3873). PFS was significantly improved for SEL + DTIC vs PBO + DTIC, median 5.6 vs 3.0 mo (HR 0.63; 80% CI 0.47, 0.84; 1-sided p=0.021). ORR was 40% with SEL + DTIC vs 26% with PBO + DTIC. Most frequent adverse events (AEs) observed with SEL + DTIC were: nausea (64%), dermatitis acneiform (52%), diarrhea (48%), vomiting (48%), and peripheral edema (43%). AEs that led to hospitalization were higher for SEL + DTIC vs PBO + DTIC (36 vs 13%), and were mostly infections and gastrointestinal disorders. The incidence of grade ≥3 AEs (68 vs 42%), serious AEs (50 vs 18%) and discontinuation of the randomized treatment due to AEs were higher for SEL + DTIC vs PBO + DTIC (16 vs 4%). Conclusions: Clinical activity was observed in patients with BRAF mutation-positive melanoma treated with SEL + DTIC, reflected by a nonsignificant improvement in OS and a significant benefit in PFS. Tolerability of this combination was generally consistent with the monotherapy safety profiles. Clinical trial information: NCT00936221.
12
Vasconcelos, Daniela C. L., Eduardo H. M. Nunes e Wander L. Vasconcelos. "AES and FTIR characterization of sol–gel alumina films". Journal of Non-Crystalline Solids 358, n. 11 (giugno 2012): 1374–79. http://dx.doi.org/10.1016/j.jnoncrysol.2012.03.017.
Testo completo
13
Hou, Yiran. "Implications of AES System of Pigai for Self-regulated Learning". Theory and Practice in Language Studies 10, n. 3 (1 marzo 2020): 261. http://dx.doi.org/10.17507/tpls.1003.01.
Testo completoAbstract (sommario):
Recent preoccupation with Chinese English-as-the-foreign-language (EFL) learners’ unsatisfying writing performance leads to a growing interest in the use of automatic essay scoring system (AES) in EFL writing in China. Pigai (www.pigai.org), being an online AES system specialised for Chinese EFL learners, has been popularised. Yet, research into Pigai is underdeveloped and constrained by simply evaluating its linguistic effectiveness; while this research innovates in investigating the efficacy of Pigai as a self-regulated learning (SRL) instrument to judge whether it should be promoted to benefit Chinese EFL learners’ writing. This study analysed and compared the changes in the quality of texts after revising via Pigai and contrasted learners’ tendency to English writing before and after the use of Pigai, ultimately examining its qualification as a SRL instrument along the sociological, pedagogical and psychological dimensions. Data for this study was collected via an experiment and follow-up interviews with undergraduate Chinese EFL learners. Results suggest that Pigai users achieved improvements in the quality of the texts and showed greater passion and persistence, as well as confidence, oriented to EFL writing. It is thus inferred that Pigai is qualified enough as a SRL instrument and could be applied into Chinese learners’ English writing.
14
Andriyanto, Ridwan, Khairijal Khairijal e Devit Satria. "Penerapan Kriptografi AES Class Untuk Pengamanan URL WEBSITE Dari Serangan SQL INJECTION". JURNAL UNITEK 13, n. 1 (29 giugno 2020): 34–48. http://dx.doi.org/10.52072/unitek.v13i1.153.
Testo completoAbstract (sommario):
Seiring penggunaan website yang semakin luas dapat menimbulkan berbagai macam tindak kejahatan seperti pencurian, manipulasi data atau informasi penting dari suatu website oleh orang yang tidak bertanggung jawab. Dalam pemrograman web terdapat dua metode untuk mengirimkan data dari client ke server, parameter POST method dan parameter GET method. GET method request menempatkan data yang dikirimkan pada URL web yang dituju. hal ini menjadi salah satu kelemahan dari GET method karena nilai variable yang dikirim menggunakan GET method dapat dilihat pada bagian URL sehingga rentan terhadap serangan SQL injection. Salah satu metode kriptografi yang dapat digunakan adalah Advanced Encryption Standard (AES). AES adalah pengganti algoritma DES (Data Encryption Standard). Hasil penelitian menunjukkan bahwa Algoritma AES dapat mengenkripsi dan mendekripsi data URL sebuah website dengan panjang kunci yang bervariasi, yaitu 128 bit, 192 bit, dan 256 bit. sehingga dapat menyamarkan informasi yang terdapat pada URL, Enkripsi URL ini menghasilkan keluaran berupa URL yang tidak menampilkan variabel asli melainkan chipertext hasil enkripsi.
15
刘, 书慧. "The Characteristics of Phosphate Adsorption on Surface Sediments in Estuary". Advances in Environmental Protection 04, n. 04 (2014): 166–72. http://dx.doi.org/10.12677/aep.2014.44023.
Testo completo
16
Neupane, Karun, Hamid Ehsan, Ahsan Wahab, Adeel Masood, Tehniat Faraz Ahmed, Saman Bahram, Abdul Hannan et al. "Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review." Journal of Clinical Oncology 39, n. 15_suppl (20 maggio 2021): e20014-e20014. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e20014.
Testo completoAbstract (sommario):
e20014 Background: Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of relapsed/refractory multiple myeloma on July 2019 and August 2020 respectively. The toxicity profile of these drugs is a concern since these are approved for use in patients who have already undergone multiple lines of treatment. Methods: Six studies for Sel and two for belamaf were included after a systematic search of PubMed, Embase, Cochrane, and Clinicaltrials.gov. Results: The most common hematological toxicity associated with these two drugs is thrombocytopenia. The common G-3/4 hematological AEs of Sel were thrombocytopenia (39%-71%), anemia (16%-33%), leukopenia (8%-33%) and neutropenia (9%-33%) whereas common G-3/4 non-hematological AEs were hyponatremia (5%-26%), fatigue (13%-15%), diarrhea (5%-10%), eye disorders (9%-10%), musculoskeletal disorders (4%-10%), elevated liver enzymes (10%), peripheral neuropathy (5%) and vomiting (2-4%). Keratopathy and anemia were the major toxicities of belamaf. Most of these toxicities are manageable. Treatment modifications and dose interruption are usually needed when AEs are more than grade II. REMS program guidelines is recommended for close monitoring and evaluation of Sel and belamaf toxicities and early ophthalmological intervention. Conclusions: As these are newer drugs with limited data, continuous surveillance and monitoring is warranted during the treatment course with early mitigation strategies. The physician should be aware of thrombocytopenia and its management as well as belamaf ocular toxicity which is manageable but if missed could have serious complications.[Table: see text]
17
Flinn, Ian, Mazyar Shadman, Benjamin Bruce Freeman, Dih-Yih Chen, Xiaoping Zhang, Aileen Cohen, Sunhee K. Ro, Jane Huang e Jeff P. Sharman. "Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib." Journal of Clinical Oncology 38, n. 15_suppl (20 maggio 2020): TPS8066. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps8066.
Testo completoAbstract (sommario):
TPS8066 Background: Ibrutinib (ibr), a Bruton tyrosine kinase inhibitor (BTKi), was shown to improve patient outcomes in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); however, adverse events (AEs) were the most common reason for discontinuing ibr (50% and 63% of discontinuations in relapse/refractory (R/R) and frontline patients, respectively; Haematologica. 2018:103:874). Zanubrutinib, an approved BTKi for mantle cell lymphoma, was specifically engineered to optimize selectivity. Pooled clinical data from 6 zanubrutinib monotherapy trials in B-cell malignancies (N=682 patients; R/R CLL/SLL [n=91]) suggested that zanubrutinib monotherapy was well tolerated and demonstrated a low rate of treatment discontinuation from AEs (9%; Tam, EHA 2019). Presented here is a trial-in-progress that will evaluate whether zanubrutinib monotherapy may serve as a therapeutic option for patients with CLL/SLL who have become ibr intolerant. Methods: The ongoing phase II, multicenter, US, single-arm, open-label study (NCT04116437, BGB-3111-215) will evaluate zanubrutinib monotherapy (160mg twice daily) as a treatment option for patients with CLL/SLL intolerant to prior ibr treatment. Approximately 60 patients will be enrolled from ~30 community medical centers. Key inclusion criteria include CLL/SLL requiring treatment per International Workshop on CLL criteria ( Blood. 2018;131:2745) before ibr therapy, intolerance to ibr (defined as an unacceptable AE for which, per investigator’s opinion, ibr treatment should be discontinued despite optimal supportive therapy), resolution of ibr-related AEs to grade ≤1 or baseline, and an ECOG PS 0-2. Key exclusion criteria include having an intervening cancer therapy between ibr and zanubrutinib, a documented disease progression during ibr treatment up to the time of enrollment, and a history of central nervous system (CNS) hemorrhage. The primary endpoint is frequency and severity of protocol-specified treatment-emergent AEs (diarrhea, myalgia, muscle spasm, arthralgia, hypertension, fatigue, rash, atrial fibrillation, and hemorrhage excluding CNS hemorrhage). The secondary endpoints include overall response rate, progression-free survival, and patient-reported outcomes. An exploratory endpoint was added to evaluate clinical effects (physical activity, treatment-related symptoms, and quality of life) using a smartphone app. Recruitment is ongoing. Clinical trial information: NCT04116437 .
18
Lu, Xiaofan, Ya Li, Jiansheng Li, Haifeng Wang, Zhaohuan Wu, Hangjie Li e Yang Wang. "Sequential Treatments with Tongsai and Bufei Yishen Granules Reduce Inflammation and Improve Pulmonary Function in Acute Exacerbation-Risk Window of Chronic Obstructive Pulmonary Disease in Rats". Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–17. http://dx.doi.org/10.1155/2016/1359105.
Testo completoAbstract (sommario):
Background. Sequential treatments of Chinese medicines for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) risk window (RW) have benefits for preventing reoccurrences of AEs; however, the effects on pulmonary function, pulmonary, and systemic inflammatory biomarkers remain unclear.Methods. Cigarette-smoke/bacterial infections induced rats were randomized into Control, COPD, AECOPD, Tongsai Granule/normal saline (TSG/NS), moxifloxacin + salbutamol/NS (MXF+STL/NS), TSG/Bufei Yishen Granule (BYG), MXF+STL/STL, and TSG+MXF+STL/BYG+STL groups and given corresponding medicine(s) in AE- and/or RW phase. Body temperature, pulmonary function, blood cytology, serum amyloid A (SAA) and C-reactive protein (CRP), pulmonary histomorphology and myeloperoxidase (MPO), polymorphonuclear (PMN) elastase, interleukins IL-1β, IL-6, and IL-10, and tumor necrosis factor- (TNF-)αexpressions were determined.Results. Body temperature, inflammatory cells and cytokines, SAA, CRP, and pulmonary impairment were higher in AECOPD rats than stable COPD, while pulmonary function declined and recovered to COPD level in 14–18 days. All biomarkers were improved in treated groups with shorter recovery times of 4–10 days, especially in TSG+MXF+STL/BYG+STL group.Conclusion. Sequential treatments with Tongsai and Bufei Yishen Granules, during AECOPD-RW periods, can reduce inflammatory response and improve pulmonary function and shorten the recovery courses of AEs, especially the integrated Chinese and Western medicines.
19
Xiao, Chunhua, Lei Zhang, Yuhua Xie, Weichen Liu e Duo Liu. "Hardware/Software Adaptive Cryptographic Acceleration for Big Data Processing". Security and Communication Networks 2018 (27 agosto 2018): 1–24. http://dx.doi.org/10.1155/2018/7631342.
Testo completoAbstract (sommario):
Along with the explosive growth of network data, security is becoming increasingly important for web transactions. The SSL/TLS protocol has been widely adopted as one of the effective solutions for sensitive access. Although OpenSSL could provide a freely available implementation of the SSL/TLS protocol, the crypto functions, such as symmetric key ciphers, are extremely compute-intensive operations. These expensive computations through software implementations may not be able to compete with the increasing need for speed and secure connection. Although there are lots of excellent works with the objective of SSL/TLS hardware acceleration, they focus on the dedicated hardware design of accelerators. Hardly of them presented how to utilize them efficiently. Actually, for some application scenarios, the performance improvement may not be comparable with AES-NI, due to the induced invocation cost for hardware engines. Therefore, we proposed the research to take full advantages of both accelerators and CPUs for security HTTP accesses in big data. We not only proposed optimal strategies such as data aggregation to advance the contribution with hardware crypto engines, but also presented an Adaptive Crypto System based on Accelerators (ACSA) with software and hardware codesign. ACSA is able to adopt crypto mode adaptively and dynamically according to the request character and system load. Through the establishment of 40 Gbps networking on TAISHAN Web Server, we evaluated the system performance in real applications with a high workload. For the encryption algorithm 3DES, which is not supported in AES-NI, we could get about 12 times acceleration with accelerators. For typical encryption AES supported by instruction acceleration, we could get 52.39% bandwidth improvement compared with only hardware encryption and 20.07% improvement compared with AES-NI. Furthermore, the user could adjust the trade-off between CPU occupation and encryption performance through MM strategy, to free CPUs according to the working requirements.
20
Byrd, John C., William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen et al. "Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results". Blood 135, n. 15 (9 aprile 2020): 1204–13. http://dx.doi.org/10.1182/blood.2018884940.
Testo completoAbstract (sommario):
Abstract Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Acalabrutinib is an oral, highly selective BTK inhibitor that allows for twice-daily dosing due to its selectivity. In this phase 1b/2 study, 134 patients with relapsed/refractory CLL or SLL (median age, 66 years [range, 42-85 years]; median prior therapies, 2 [range, 1-13]) received acalabrutinib 100 mg twice daily for a median of 41 months (range, 0.2-58 months). Median trough BTK occupancy at steady state was 97%. Most adverse events (AEs) were mild or moderate, and were most commonly diarrhea (52%) and headache (51%). Grade ≥3 AEs (occurring in ≥5% of patients) were neutropenia (14%), pneumonia (11%), hypertension (7%), anemia (7%), and diarrhea (5%). Atrial fibrillation and major bleeding AEs (all grades) occurred in 7% and 5% of patients, respectively. Most patients (56%) remain on treatment; the primary reasons for discontinuation were progressive disease (21%) and AEs (11%). The overall response rate, including partial response with lymphocytosis, with acalabrutinib was 94%; responses were similar regardless of genomic features (presence of del(11)(q22.3), del(17)(p13.1), complex karyotype, or immunoglobulin variable region heavy chain mutation status). Median duration of response and progression-free survival (PFS) have not been reached; the estimated 45-month PFS was 62% (95% confidence interval, 51% to 71%). BTK mutation was detected in 6 of 9 patients (67%) at relapse. This updated and expanded study confirms the efficacy, durability of response, and long-term safety of acalabrutinib, justifying its further investigation in previously untreated and treated patients with CLL/SLL. This trial was registered at www.clinicaltrials.gov as #NCT02029443.
21
Ronchi de Souza, Bruno, Brunella Flores Pupo, Eveline Geller, Francielle Lazzarin de Freitas Gava e Ioná Vieira Bez Birolo. "SENSIBILIZAÇÃO DE AGENTES COMUNITÁRIAS DE SAÚDE SOBRE CAPTAÇÃO PRECOCE DE GESTANTES". Revista de Extensão 1, n. 1 (1 giugno 2016): 64. http://dx.doi.org/10.18616/re.v1i1.2419.
Testo completoAbstract (sommario):
<p>Trata-se de um estudo exploratório, qualitativo, resultado de um projeto de extensão da Universidade do Extremo Sul Catarinense - UNESC, UNASAU, curso de enfermagem, com objetivo de identificar de que forma as Agentes Comunitárias de Saúde (ACS) de uma Estratégia Saúde da Família (ESF) de um município do extremo sul catarinense fazem a captação precoce de suas gestantes a partir de seis questões aplicadas durante um encontro para sensibilização das mesmas. Participaram 33 ACS. Os dados qualitativos foram categorizados por análise de conteúdo de Minayo. Observou-se que as ACS estão bem informadas sobre sua atuação nas unidades de saúde, porém não conheciam muito sobre a Rede Cegonha. Assim evidencia-se a necessidade de realizar mais oficinas de discussão para aprimorar o aprendizado e instrumentar esses profissionais tão importantes para o vínculo da comunidade com as unidades de saúde.</p>
22
Hadi, Albertus Radityo, e Maria Irmina Prasetiyowati. "Rancang Bangun Aplikasi Transport Booking Berbasis Android dengan Teknik Enkripsi Advanced Encryption Standard". Jurnal ULTIMATICS 4, n. 2 (1 dicembre 2012): 16–21. http://dx.doi.org/10.31937/ti.v4i2.315.
Testo completoAbstract (sommario):
Pemesanan kendaraan pada PT Indodev Niaga Internet saat ini hanya dapat dilakukan melalui komputer. Hal ini kurang efektif apabila karyawan ada tugas mendadak dan harus memesan terlebih dahulu melalui komputer. Guna mengatasi hal tersebut, maka perlu dibangun suatu aplikasi yang diimplementasikan pada perangkat yang mudah di akses setiap saat, yaitu telepon genggam. Aplikasi ini dibangun pada telepon genggam berbasis Android dengan bahasa pemprograman Java, menggunakan basis data SQL Server, dan untuk menjaga keamanan data yang dikirimkan menggunakan teknik enkripsi Advance Encryption Standard (AES).
Kata kunci — aplikasi pemesanan kendaraan, Android, PT Indodev Niaga Internet, AES
23
Shindiapina, Polina, Soun Khountham, Kerry A. Rogers, Jeffrey Jones, Leslie Andritsos, Kami J. Maddocks, Joseph M. Flynn, Jennifer A. Woyach, John C. Byrd e Farrukh T. Awan. "Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL". Blood 128, n. 22 (2 dicembre 2016): 4385. http://dx.doi.org/10.1182/blood.v128.22.4385.4385.
Testo completoAbstract (sommario):
Abstract Introduction: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib (IB) is currently approved for the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), including patients with del17p disease. Treatment with IB is effective and generally well-tolerated. However, a proportion of patients experience intolerable adverse events (AEs) requiring IB discontinuation. Non-infectious toxicities are generally considered to be due to kinase inhibition and it is uncertain if the AE is directly attributable to inhibition of BTK (on-target effect) or to inhibition of an alternative target of ibrutinib (off-target effect). To indirectly examine this, we reviewed toxicity and tolerability data for patients who discontinued IB due to significant AEs and subsequently received an alternative BTK inhibitor. Methods: Patients with previously treated CLL/SLL who were intolerant to IB due to non-infectious IB-attributable AEs and subsequently received a different BTK inhibitor were included in this analysis. Patients with infectious AEs were excluded. AEs arising during IB therapy that were attributable to IB and resulted in discontinuation based on both patient and investigator preference were detailed and graded according to CTCAE v.4.03. These AEs were assessed for resolution or increasing severity after discontinuing IB both before and during subsequent BTK inhibitor treatment. Results: Twenty-one patients were included in the analysis and the median age was 61-years (range 50-76). Patients had received a median of 4 prior therapies (range 2-11). Fifty-eight percent of the patients had Rai stage 3-4 disease, 76% were IGHV un-mutated, and 57% had del17p. Prevalent co-morbidities by organ system prior to start of acalabrutinib included blood and lymphatic system disorders (48%), infectious issues (52%), cardiac disorders (38%), gastrointestinal disorders (43%) and musculoskeletal disorders (33%). Median time on IB was 13 months (range 1.6-62). Reasons for IB discontinuation are detailed in Table 1. With regards to more severe (grade 3 or 4) IB-attributable AEs, 2 patients experienced grade 4 AEs resulting in discontinuation of IB including neutropenia and subdural hematoma. Both these patients had resolution of their AEs prior to starting subsequent treatment. Among the 14 patients discontinuing IB for grade 3 AEs, 1 had ongoing grade 3 diarrhea, 1 had grade 3 arthralgia, and 2 had grade 2 AEs of diarrhea and fatigue at the time of starting subsequent treatment. Of the 21 included patients, 10 had ongoing IB-attributable grade 1-3 AEs at the time of starting a different BTK inhibitor. Three of these patients experienced resolution of one or more IB-attributable AEs (grade 3 diarrhea, and grade 2 AEs including panniculitis, arthralgia and diarrhea) within 28 days of starting therapy, 6 patients had stable grade 1-2 AEs (grade 1 rash in 2 patients, grade 2 diarrhea, grade 1 arthralgia, grade 1 abdominal pain, grade 2 fatigue) at last follow up while taking alternate BTK inhibitor, and 1 patient with an ongoing grade 2 AE at time of treatment initiation developed CNS involvement with their malignancy and was taken off therapy prior to assessment for resolution of the AE. The remaining 11 patients had either complete resolution or improvement of the AE to grade 1 prior to starting the treatment. No recurrence or worsening of IB-attributable AEs were observed during a median follow-up of 13-months on alternative treatment except for 1 patient with hemophilia A, who developed grade 3 hematoma while on IB therapy and experienced recurrent hematoma after 5 days of treatment with a different BTK inhibitor, at which time the drug was discontinued. Conclusions: For patients who discontinued IB due to non-infectious IB-attributable AEs, subsequent treatment with an alternative BTK inhibitor does not appear to aggravate or precipitate IB-attributable AEs that had previously resulted in discontinuation. This supports attribution of these AEs to off-target effects of ibrutinib and not inhibition of BTK. The use of an alternate BTK inhibitor may be a viable therapeutic strategy for patients who discontinued IB due to intolerable AEs without experiencing clinical progression. Disclosures Jones: Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics, LLC, an AbbVie Company: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding. Woyach:Karyopharm: Research Funding; Morphosys: Research Funding; Acerta: Research Funding. Awan:Innate Pharma: Research Funding; Novartis Oncology: Consultancy; Pharmacyclics: Consultancy.
24
Pramukantoro, Eko Sakti, Fariz Andri Bakhtiar, Ahmad Lutfi Bayu Aji e Deny Hari Prasetya Dewa. "Implementasi Mekanisme End-To-End Security pada IoT Middleware". Jurnal Teknologi Informasi dan Ilmu Komputer 6, n. 3 (9 maggio 2019): 335. http://dx.doi.org/10.25126/jtiik.2019631401.
Testo completoAbstract (sommario):
<p class="Abstrak">Pada penelitian sebelumnya telah dikembangkan sebuah <em>middleware</em> dengan pendekatan <em>event-driven</em> yang mampu mendukung interoperabilitas berbagai macam perangkat sensor pada lingkungan IoT. Namun, skema komunikasi pada <em>middleware</em> tersebut masih terdapat celah keamanan dan menimbulkan ancaman berupa <em>eavasdropping</em>. Solusi dari permasalahan ini adalah menerapakan mekanisme <em>end-to-end security</em>. Dalam penelitian ini dilakukan penerapan algoritme kriptografi AES-CBC 128 pada komunikasi node sensor ke <em>middleware</em> dan mekanisme TLS pada komunikasi <em>middleware</em> dengan aplikasi berbasis IoT. Hasil yang didapat <em>end-to-end security</em> berbasis kriptografi pada pub/sub dapat menjamin kerahasiaan data dengan enkripsi payload akan tetapi topik masih terlihat, sedangkan TLS/SSL menjamin kerahasiaan seluruh data yang dikirim. Penggunaan mekanisme ini tidak berdampak signifikan pada <em>delay</em> pengiriman data, yaitu masih dibawah 1 detik</p><p class="Abstrak"> <em><strong>Abstract</strong></em></p><p class="Abstrak"><em>An IoT middleware for handling interoperability is proposed in previous works. However, a vulnerability that can lead to the eavesdropping attack exist. there is no security mechanism in the communication system among middleware with other parties like node sensors and subscribers. This research implements the end to end security to the existing IoT middleware. AES-CBC 128 is used to secure communication between sensor nodes to middleware and used TLS/SLL between middleware and subscriber. The results show both mechanisms can securely communication between middleware and other parties, but AES-CBS can only secure data payload, not entire data. This mechanism has no significant impact on the delay transmission, which is still under 1 second</em></p>
25
Smith, R. Theodore. "Sub-threshold nanosecond laser (SNL) treatment in intermediate AMD (IAMD)". Annals of Eye Science 4 (gennaio 2019): 2. http://dx.doi.org/10.21037/aes.2018.12.04.
Testo completo
26
Delcorno, Pietro. "Catechesi e drammatizzazione: Lo Spirito Santo nei sermoni di Pentecoste di Vicent Ferrer". Anuario de Estudios Medievales 49, n. 1 (2 aprile 2019): 75. http://dx.doi.org/10.3989/aem.2019.49.1.03.
Testo completoAbstract (sommario):
[it] L’articolo si concentra sull’abilità comunicativa di Vicent Ferrer e sulla sua capacità di miscelare catechesi e invenzione narrativa, analizzando sei versioni del sermone Repleti sunt omnes Spiritu Sancto. Gli schemi, le reportationes, i sermoni modello delle prediche tenute da Ferrer in diverse parti d’Europa mostrano come la festa di Pentecoste fornisse l’occasione per una vivace ‘messa in scena’ del racconto biblico e come la predicazione fornisse agli ascoltatori un accesso, mediato ma non banale, alla conoscenza della Scrittura. Nel sermone di Pentecoste, indicando la comunità apostolica come modello per i suoi ascoltatori, Ferrer sviluppava una riflessione tanto sul ruolo della predicazione quanto sul disporsi ad accogliere lo Spirito Santo.
27
Barr, Paul M., Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan Andreas Burger, Peter Hillmen et al. "Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia." Journal of Clinical Oncology 39, n. 15_suppl (20 maggio 2021): 7523. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7523.
Testo completoAbstract (sommario):
7523 Background: Ibrutinib, a once-daily Bruton’s tyrosine kinase inhibitor, is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized phase 3 studies versus established therapies in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Extended long-term follow-up data for the RESONATE-2 study of first-line ibrutinib vs chlorambucil in older pts with CLL/SLL are reported. Methods: In the phase 3 RESONATE-2 study, older pts (≥65 years [y]) with previously untreated CLL/SLL and without del(17p) (N=269) were randomly assigned 1:1 to once-daily single-agent ibrutinib 420 mg until disease progression (PD) or unacceptable toxicity (n=136) or chlorambucil 0.5–0.8 mg/kg up to 12 cycles (n=133). Outcomes included PFS, OS, overall response rate (ORR), and safety. Long-term responses were investigator-assessed per 2008 iwCLL criteria. Results: With up to 7y of follow-up (median, 74.9 months; range, 0.1–86.8), significant PFS benefit was sustained for pts treated with ibrutinib vs chlorambucil (hazard ratio [HR] 0.160 [95% confidence interval (CI): 0.111–0.230]). At 6.5y, PFS was 61% in pts treated with ibrutinib vs 9% in pts treated with chlorambucil. This PFS benefit was observed across all subgroups, including in ibrutinib-treated pts with high-risk genomic features of unmutated IGHV (HR 0.109 [95% CI: 0.063–0.189]) or del(11q) (HR 0.033 [95% CI: 0.010–0.107]). OS at 6.5y was 78% with ibrutinib treatment. ORR was 92% for ibrutinib-treated pts with complete response (CR/CRi) rate increasing to 34% with this follow-up. Ongoing rates of grade ≥3 adverse events (AEs) of interest remained low for hypertension (5–6y interval: 5%, n=4; 6–7y: 4%, n=3) and atrial fibrillation (5–6y: 1%, n=1; 6–7y: 1%, n=1); no grade ≥3 major hemorrhage occurred in 5–7y. Dose reductions due to grade ≥3 AEs occurred in 1% (n=1) of pts during the 5–6y and 6–7y intervals. Across full follow-up, 31 pts had dose reductions due to any-grade AEs of whom 22/31 (71%) had resolution or improvement the AE. Primary reason for discontinuations in 5–7y was PD (5–6y: 5%, n=4; 6–7y: 6%, n=4). Any-grade AEs leading to discontinuations were seen in 3% (n=2) of pts from 5–6y and none in 6–7y. With over 7y of follow-up, 47% of pts remain on single-agent ibrutinib. Conclusions: Extended long-term data from RESONATE-2 demonstrate the sustained PFS and OS benefit of first-line ibrutinib treatment for pts with CLL, including for pts with high-risk genomic features. Responses continue to deepen over time. Rates of grade ≥3 AEs of interest continued to be low at up to 7y follow-up and further discontinuations and dose reductions due to AEs were rare; most AEs leading to dose reduction resolved or improved. Ibrutinib remains well tolerated with no new safety signals observed. Clinical trial information: NCT01722487, NCT01724346.
28
Alecrim Cardoso, Ana Karoliny. "QUALIDADE DE VIDA E SATISFAÇÃO NO TRABALHO DE AGENTES COMUNITÁRIOS DE SAÚDE". DESAFIOS - Revista Interdisciplinar da Universidade Federal do Tocantins 7, n. 3 (1 settembre 2020): 187–97. http://dx.doi.org/10.20873/uftv7-8083.
Testo completoAbstract (sommario):
Introdução: Agente Comunitário de Saúde (ACS), é o principal agente social da Estratégia de Saúde da Família constituindo o elo entre o serviço e a comunidade, sendo imprescindível nesse cenário. Assim, faz-se necessário avaliar a Qualidade de Vida no Trabalho (QVT) e a Satisfação no Trabalho (ST), visto que possuem relação com a produtividade e alcance dos objetivos organizacionais. Objetivo: avaliar a QVT e a ST dos ACS da região sul de Palmas-TO. Metodos e Materiais: Estudo descritivo, exploratório, quantitativo realizado com 27 ACS dos Centros de Saúde da Comunidade da região sul de Palmas- TO. Utilizou-se o Quality of Working Life Questionnaire - QWLQ-bref e o Questionário de Satisfação no Trabalho S20/S23. Resultados: O escore total médio para QVT foi 3,49, variando de 1,90 a 4,55 e o escore total médio para ST foi 3,40, variando de 1,80 a 5,00. Conclusão: Verificou-se índices elevados de QVT e de ST. Os escores dos domínios da QVT apresentaram correlação positiva moderada ou forte com os fatores da ST, demonstrando na amostra estudada, quanto maior a qualidade de vida no trabalho, maior a satisfação no trabalho.
29
Utami, Hamdan Dian Jaya Rozi Hyang, Riza Arifudin e Alamsyah Alamsyah. "Security Login System on Mobile Application with Implementation of Advanced Encryption Standard (AES) using 3 Keys Variation 128-bit, 192-bit, and 256-bit". Scientific Journal of Informatics 6, n. 1 (24 maggio 2019): 34–44. http://dx.doi.org/10.15294/sji.v6i1.17589.
Testo completoAbstract (sommario):
The development of mobile applications is unbalanced with the level of its security which is vulnerable to hacker attacks. Some important things that need to be considered in the security of mobile applications are login and database system. A login system that used the database as user authentication and passwords are very vulnerable to be hacking. In securing data, various ways had been developed including cryptography. Cryptographic algorithms used in securing passwords usually used MD5 encryption. However, MD5 as a broader encryption technique is very risky. Therefore, the level of login system security in an android application is needed to embed the Advanced Encryption Standard (AES) algorithm in its process. The AES algorithm was applied using variations of 3 keys 128-bit, 192-bit, and 256-bit. Security level testing was also conducted by using 40 SQL Injection samples which the system logins without security obtained 27.5% that be able to enter the system compared to the result of login systems that use AES algorithm 128-bit, 192-bit or 256-bit was obtained 100% that cannot enter into the system. The estimation of the average encryption process of AES 128, 192 and 256 bits are 5.8 seconds, 7.74 seconds, and 9.46 seconds.
30
Shanthi Rekha, S., e P. Saravanan. "Low-Cost AES-128 Implementation for Edge Devices in IoT Applications". Journal of Circuits, Systems and Computers 28, n. 04 (31 marzo 2019): 1950062. http://dx.doi.org/10.1142/s0218126619500622.
Testo completoAbstract (sommario):
Internet of Things (IoT) is an ecosystem of connected edge devices that are accessible through the internet. Recent research focusses on adding more smartness and intelligence to these edge devices making them susceptible to various kinds of security threats. These edge devices rely on cryptographic techniques to encrypt the pre-processed data collected from the sensors deployed in the field. Since the edge devices are resource constrained, low-cost implementations of cryptographic algorithms are desirable. This work proposes a novel low-cost implementation of a versatile symmetric encryption algorithm namely Advanced Encryption Standard (AES) using time-multiplexed architectures for edge devices. The optimization is carried out in a four-fold manner on AES encryption/decryption hardware based on the resource sharing mechanism with a modified Substitution box achieving a maximum of 1.053[Formula: see text]GHz operating frequency. The aim of this work is to develop an area-power efficient AES architecture with a reasonable throughput suitable for resource constrained applications. The proposed architectures are synthesized on a Virtex-6 FPGA board and the ASIC performance results are obtained using 180[Formula: see text]nm SCL technology library. Implementation results of the proposed AES core integrated with an UART module are shown as a proof of concept.
31
Wienhold, F. G., J. Anders, B. Galuska, U. Klocke, M. Knothe, W. J. Riedel, G. Schmidtke, R. Singler, U. Ulmer e H. Wolf. "The solar package on ISS: SOL-ACES". Physics and Chemistry of the Earth, Part C: Solar, Terrestrial & Planetary Science 25, n. 5-6 (gennaio 2000): 473–76. http://dx.doi.org/10.1016/s1464-1917(00)00060-x.
Testo completo
32
GRANADO-CRIADO, JOSE M., MIGUEL A. VEGA-RODRÍGUEZ, JOSE M. CHAVES-GONZALEZ, JUAN M. SANCHEZ-PEREZ e JUAN A. GOMEZ-PULIDO. "LOW POWER CONSUMPTION SECURITY PLATFORM FOR INDUSTRIAL COMMUNICATIONS USING AN MPSOC". Journal of Circuits, Systems and Computers 22, n. 05 (9 maggio 2013): 1350029. http://dx.doi.org/10.1142/s0218126613500291.
Testo completoAbstract (sommario):
This work presents a novel security platform for industrial communications using a nine-MicroBlaze MPSoC. This platform has low power consumption and cost, therefore, it is very appropriate for embedded systems, where restrictions on cost and power consumption have to be fulfilled. This system uses the RSA asymmetric algorithm combined with the AES symmetric algorithm, which was developed using two encryption modes, ECB and CBC. In this way, the platform makes possible to combine different algorithms and modes in function of the necessities of speed and security required. Furthermore, due to the implementation of standard algorithms (AES and RSA) and modes (ECB and CBC), this platform can be connected to the Internet, and can even use secure protocols as SSL.
33
Flinn, Ian W., Marco Montillo, Zsolt Nagy, Zoltán Gasztonyi, Matthew S. Davids, Klaus Geissler, Jose J. Rifon Roca et al. "Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies". Blood 132, Supplement 1 (29 novembre 2018): 3146. http://dx.doi.org/10.1182/blood-2018-99-120027.
Testo completoAbstract (sommario):
Abstract Background: Duvelisib (DUV) is a first-in class, oral dual inhibitor of PI3K-δ,-γ being developed for the treatment of advanced B- and T-cell malignancies. To date 304 patients (pts) with relapsed/refractory (RR) CLL/SLL have been treated with DUV monotherapy 25 mg BID in 4 studies: Study IPI-145-02 [NCT01476657], a Phase 1 study in advanced hematologic malignancies; DYNAMOTM [NCT01882803], a Phase 2 study in iNHL; DUOTM [NCT02004522], a Phase 3 study in CLL/SLL; and Study IPI-145-12 [NCT02049515], a Phase 3 crossover study from DUO. Here we present pooled efficacy and safety analyses from these 4 studies in RR CLL/SLL, examining the baseline characteristics, incidence and timing of AEs, and response in the subset of pts who received DUV monotherapy for >2 years in order to characterize the factors that contribute to long-term treatment with DUV. Methods: In this analysis we examined pts treated with DUV for >2 years (n=45) referred to as long-term (LT) pts. Efficacy and safety data from 4 studies of DUV monotherapy in pts with RR CLL/SLL treated at 25 mg BID were pooled. Response was based on investigator assessment per IWCLL/IWG criteria. Treatment-emergence (TE) was defined as those adverse events (AEs) that occurred from first dose to 30 days post last dose of DUV. All AEs were coded using MedDRA version 16.1; severity was assessed by investigators according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03. Results: Baseline characteristics of LT pts were similar to pts who discontinued <2 years. The median age for LT pts was 68 years (range: 45-90 years); 58% were male and 20% had del(17p) and/or TP53 mutation. LT pts had a median of 2 prior therapies, with 44% having received ≥3 prior therapies. Most pts (76%) had prior chemoimmunotherapy (alkylator based [73%]; purine based [38%]). The median exposure for LT pts was 31 months, with 20 pts on DUV >3 years and 3 pts on DUV >4 years. The majority of LT pts (60%) remain on treatment as of June 2018. The median PFS in LT pts was 37 months, with an investigator-assessed ORR of 89%; best responses included 16% CR/CRi, 73% PR, and 11% SD. Among LT pts, 98% had an AE, 80% had a ≥ Gr 3 AE, 46% an SAE, and 9% an AE leading to discontinuation (after 2 years on DUV); 69% of pts had at least 1 dose modification due to an AE (69% hold, 40% reduction). Table 1 shows the incidence of AEs in LT pts by 6-month treatment intervals. Overall, ≥ Gr 3 AEs occurred less frequently over time but still occurred in 27% pts after 2 years. The rate of colitis was consistent over the 2 years of treatment (≤ 2.2% per 6-month interval). No ≥ Gr 3 AEs of diarrhea were observed within the first 6 months of treatment, while the overall rate of all grade diarrhea was consistent over time (16-27% per 6-month interval); dose modification for the management of diarrhea increased over time allowing pts to remain on therapy. Neutropenia, ALT increase, and lipase increase were more common in the first 6 months; most ≥ Gr 3 AEs of neutropenia did not require any dose modification. Compared to all pts with RR CLL/SLL treated with DUV (n=442), the incidences and types of AEs in LT pts were generally similar. Four (9%) LT pts discontinued DUV due to an AE, and included: colitis (n=2), diarrhea (n=1), Clostridium difficile colitis (n=1), and rectal adenocarcinoma (n=1). Pneumocystis jirovecii pneumonia occurred in 1 LT pt (not on prophylaxis at the time) and was the only opportunistic infection reported for this population. There have been no fatal events in the LT pts. Conclusions: 45 pts with RR CLL/SLL have been on DUV 25 mg BID for >2 years, with a median of 31 months on treatment. The investigator-assessed ORR for these long-term pts was 89% (16% CR/CRi, 78% PR) and the median PFS was 37 months. A majority (60%) of the long-term pts remain on treatment. Baseline characteristics were similar in these long-term pts compared to pts who discontinued < 2 years. Most of the commonly occurring ≥ Gr 3 AEs decreased over time, with the exception of diarrhea. The majority of ≥ Gr 3 AEs were managed through dose modification (dose interruption and or reduction). These data support DUV monotherapy as a long-term treatment option for pts with RR CLL/SLL with the potential for durable response and good tolerability over time. Disclosures Flinn: ArQule: Research Funding; Infinity: Research Funding; Verastem: Research Funding; BeiGene: Research Funding; Curis: Research Funding; Merck: Research Funding; Seattle Genetics: Research Funding; Agios: Research Funding; Forma: Research Funding; Portola: Research Funding; Kite: Research Funding; Forty Seven: Research Funding; Genentech: Research Funding; Gilead: Research Funding; Celgene: Research Funding; Verastem: Consultancy, Research Funding; Incyte: Research Funding; Janssen: Research Funding; Takeda: Research Funding; TG Therapeutics: Research Funding; Pharmacyclics: Research Funding; Pfizer: Research Funding; Trillium: Research Funding; Novartis: Research Funding; Calithera: Research Funding; Constellation: Research Funding. Montillo:Roche: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau. Davids:BMS: Research Funding; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy; Merck: Consultancy; Surface Oncology: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; MEI Pharma: Consultancy, Research Funding; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees. Le:Verastem Oncology: Employment. Lustgarten:Verastem Oncology: Employment.
34
Coutre, Steven, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak et al. "Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)". Blood 128, n. 22 (2 dicembre 2016): 4383. http://dx.doi.org/10.1182/blood.v128.22.4383.4383.
Testo completoAbstract (sommario):
Abstract Background: Ibrutinib (ibr), a first-in-class, oral once-daily inhibitor of Bruton's tyrosine kinase, is indicated by the US FDA for the treatment of pts with CLL/SLL and allows for treatment without chemotherapy. Unlike chemotherapy that is given for a finite number of cycles, ibr is continued until progressive disease (PD) or unacceptable toxicity, leading to extended ibr treatment duration in many patients. The objective was to examine safety and tolerability of ibr therapy in pts with treatment-naïve (TN) or relapsed/refractory (R/R) CLL/SLL using an integrated safety analysis approach, and conduct an analysis of long-term safety. Methods: In study PCYC-1112 (RESONATE), pts with R/R CLL/SLL received ibr 420 mg orally once-daily vs. ofatumumab (Byrd, N Engl J Med 2015). In study PCYC-1115 (RESONATE-2), pts age ≥65 years with TN CLL/SLL received ibr 420 mg orally once-daily vs. chlorambucil (Burger, N Engl J Med 2015). Progressing pts could enroll in the extension study PCYC-1116 for next line therapy (including ibr). Data from ibr-treated pts from the above randomized controlled studies were pooled for an integrated safety analysis. In study PCYC-1102, pts with TN or R/R CLL/SLL received ibr 420 mg or 840 mg orally once-daily (Byrd, N Engl J Med 2013; O'Brien, Lancet Oncol 2014). Pts could continue receiving ibr in the long-term extension study PCYC-1103 where adverse event (AE) collection was limited to grade ≥3 AEs, major hemorrhage, or AEs leading to ibr dose modification. Only data from pts treated with ibr 420 mg daily were examined herein. Results: The integrated analysis included 330 pts; 51% Rai III/IV, 54% bulky disease ≥5 cm, 28% del11q, and 37% CrCl <60 mL/min. Pts received ibr for a median of 29.0 mo (max 42.9); 280 (85%) treated for >1 year, 193 (58%) for >2-3 years, and 53 (16%) for >3 years. Concomitant medications included 50% antiplatelet agents, 28% anticoagulants, 3% granulocyte growth factors, and 2% IVIG. The most common AEs were diarrhea (53%) and fatigue (36%). Other AEs experienced by ≥25% of pts were upper respiratory tract infection (30%), nausea (29%), pyrexia (28%), and anemia (27%). Grade ≥3 AEs reported in ≥5% of pts were neutropenia (18%), pneumonia (12%), anemia (7%), and hypertension (HT, 6%). AEs of interest were primarily grade 1/2 (Table). AEs of any grade that led to dose reductions and discontinuation were reported in 13% and 19% of pts, respectively. AEs leading to discontinuation in >1 pt were pneumonia (n=4), anemia (n=3), atrial fibrillation (AFib, n=3), diarrhea (n=2), subdural hematoma (n=2), and thrombocytopenia (n=2). 29 pts died (9%), the most common causes of death were PD (n=8), and pneumonia/lung infection (n=7). In PCYC-1102/1103, 94 pts were treated with ibr for a median of 47.9 mo (max 67.4 mo). The most frequent grade ≥3 AEs were similar to those observed in PCYC-1112 or PCYC-1115/1116, and at times, reflect higher cumulative rates given the median 19 additional months of treatment and follow-up; grade ≥3 AEs reported in ≥5% of pts were hypertension (30%), pneumonia (17%), neutropenia (15%) atrial fibrillation (11%), diarrhea (9%), cellulitis (7%), thrombocytopenia (7%), hyperglycemia (7%), fatigue (6%), decrease in lymphocyte count (6%), and sepsis (5%). Most frequent malignancies included basal cell carcinoma (n=4), squamous cell carcinoma (n=4), and myelodysplastic syndromes (n=2). In 7 of 15 pts, the malignancy AE was diagnosed during the first year, while others occurred over time throughout the ongoing follow-up of >4 years. Overall survival for R/R pts was 74% at 36 mo in PCYC-1112, and 62% at 60 mo in PCYC-1102/1103. Survival of TN pts was 95% at 24 mo in PCYC-1115/1116, and 91% at 60 mo in PCYC-1102/1103 (Kaplan-Meier estimates). Conclusions: In these analyses, which included up to 5 years of follow up in TN and R/R CLL treated with single agent ibr, AEs were primarily grade 1/2 and were manageable with prolonged treatment. Disclosures Coutre: Janssen: Consultancy; Pharmacylics, LLC, an AbbVie Company: Consultancy, Research Funding; AbbVie: Research Funding. Hillmen:Pharmacyclics: Research Funding; Janssen: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Abbvie: Research Funding. Barr:Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; AbbVie: Consultancy. Devereux:Roche: Consultancy, Other: Travel, Accommodations, Expenses ; Gilead: Consultancy, Other: Travel, Accommodations, Expenses, Speakers Bureau; Janssen: Consultancy, Other: Travel, Accommodations, Expenses, Speakers Bureau; GSK: Consultancy. Robak:Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. Kipps:Celgene: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria. Schuh:Roche: Consultancy, Honoraria; GSK: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria. Furman:Genentech: Consultancy; Janssen: Consultancy; Abbvie: Consultancy, Honoraria; Gilead Sciences: Consultancy; Pharmacyclics: Consultancy, Speakers Bureau. Burger:Janssen: Consultancy, Other: Travel, Accommodations, Expenses; Roche: Other: Travel, Accommodations, Expenses; Gilead: Research Funding; Pharmacyclics, LLC, an AbbVie Company: Research Funding; Portola: Consultancy. O'Dwyer:Roche: Other: Travel, accommodations, expenses; Novartis: Consultancy; Glycomimetics: Consultancy; Amgen: Consultancy, Other: Travel, Accommodations, Expenses ; BMS: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Equity Ownership, Honoraria, Research Funding; NUI Galway: Patents & Royalties. Ghia:Abbvie: Consultancy, Honoraria; Adaptive: Consultancy; Gilead: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Roche: Honoraria, Research Funding. Valentino:Gilead: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment, Other: Travel, accommodations, and expenses; AbbVie: Equity Ownership; Corvus: Equity Ownership; Johnson and Johnson: Equity Ownership, Other: Travel, accommodations, and expenses. Suzuki:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment, Other: Leadership; Travel, Accommodations, Expenses. Ninomoto:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment; Amgen: Equity Ownership. James:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment. O'Brien:Janssen: Consultancy, Honoraria; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding.
35
Kuda, Takashi, Maki Nemoto, Miho Kawahara, Satoshi Oshio, Hajime Takahashi e Bon Kimura. "Induction of the superoxide anion radical scavenging capacity of dried ‘funori’ Gloiopeltis furcata by Lactobacillus plantarum S-SU1 fermentation". Food & Function 6, n. 8 (2015): 2535–41. http://dx.doi.org/10.1039/c5fo00668f.
Testo completoAbstract (sommario):
To understand the beneficial properties of edible algae obtained from the north-eastern (Sanriku) Satoumi region of Japan, the antioxidant properties of hot aqueous extract solutions (AES) obtained from 18 dried algal products were determined.
36
Muttaqin, Muhammad Farras. "Implementation of AES-128 and Token-Base64 to Prevent SQL Injection Attacks via HTTP". International Journal of Advanced Trends in Computer Science and Engineering 9, n. 3 (25 giugno 2020): 2876–82. http://dx.doi.org/10.30534/ijatcse/2020/60932020.
Testo completo
37
Reymao, Ana Elizabeth Neirao, e Karla Azevedo Cebolão. "A Análise Econômica do Direito no Tribunal de Justiça do Rio Grande do Sul: um estudo sobre o caso dos fumicultores e as concessionárias de energia elétrica". Revista de Direito, Economia e Desenvolvimento Sustentável 5, n. 1 (22 ottobre 2019): 1. http://dx.doi.org/10.26668/indexlawjournals/2526-0057/2019.v5i1.5377.
Testo completoAbstract (sommario):
O artigo objetiva discutir decisões judiciais que empregam a Análise Econômica do Direito (AED), apresentando um estudo de caso sobre o litígio entre os fumicultores gaúchos e as concessionárias de energia elétrica, no Tribunal de Justiça do Estado do Rio Grande do Sul (TJRS). A pesquisa é de abordagem qualitativa, com levantamento bibliográfico e documental, notadamente a jurisprudência sobre o tema. Mostra-se que, desde fins de 2016, essas disputas judiciais têm sido decididas com base em conceitos da AED, concluindo o TJRS pela divisão do prejuízo entre os fumicultores e as concessionárias.
38
Cazola, Luiza Helena de Oliveira, Edson Mamoru Tamaki e Elenir Rose Jardim Cury Pontes. "Incorporação do controle da dengue pelo agente comunitário de saúde". Revista Brasileira de Enfermagem 67, n. 4 (agosto 2014): 637–45. http://dx.doi.org/10.1590/0034-7167.2014670421.
Testo completoAbstract (sommario):
O estudo objetivou caracterizar as diferenças no processo de trabalho de agentes comunitários de saúde (ACS) em dois municípios sul-mato-grossenses, segundo sua percepção, frente às atividades desenvolvidas no controle da dengue e na saúde da família. Aplicaram-se entrevistas estruturadas a 57 ACS. Constatou-se que os ACS apresentavam características sociodemográficas semelhantes. Os de Rio Verde de Mato Grosso, que executavam apenas ações da saúde da família, não priorizaram o preenchimento da Ficha A. Em São Gabriel do Oeste, os ACS incorporaram as atividades do controle da dengue, extinguindo-se o Agente de Controle de Endemias, enquanto em Rio Verde de Mato Grosso ambos se mantiveram. Na percepção dos ACS de São Gabriel do Oeste, a acumulação dos dois programas não influiu em sua produtividade. A unificação das ações dos dois programas em um mesmo profissional se mostrou viável, sem prejuízos às atividades desenvolvidas.
39
Alves, Anelise Dorneles, Iane Franceschet de Sousa, Daiane Biff e Evelyn Elias. "Impacto da reformulação da Política Nacional de Atenção Básica no processo de trabalho dos Agentes Comunitário de Saúde em um município do sul do Brasil". Research, Society and Development 9, n. 10 (20 ottobre 2020): e8039109198. http://dx.doi.org/10.33448/rsd-v9i10.9198.
Testo completoAbstract (sommario):
A publicação da Política Nacional de Atenção Básica (PNAB) 2017 trouxe mudanças significativas em relação à atuação dos Agentes Comunitários de saúde (ACS), aliado a isto nota-se também dificuldade em estabelecer processos avaliativos ao trabalho deste profissional. Esta pesquisa tem como objetivo avaliar o processo de trabalho dos ACS do município de Araranguá/SC, possibilitando um comparativo do cenário antes e após publicação da PNAB de 2017. Os dados foram coletados através de entrevistas estruturadas nas 15 Unidades Básicas de Saúde (UBS), sendo realizadas em três fases. A primeira direcionada ao conhecimento do ACS, a segunda direcionada a dois moradores de residências distintas e, por último, o questionário destinado a um funcionário onde o ACS atua. Foram entrevistados 19 ACS quando ainda vigorava a PNAB 2011 e 14 ACS após a publicação da PNAB em 2017. Não houve diferenças significativas na comparação de questões referentes ao processo de trabalho dos ACS. Todavia, em questões relacionadas às visitas domiciliares observamos queda com a nova vigência, além disso, notamos um maior conhecimento sobre áreas de risco pertencentes à área de atuação do agente. Os resultados evidenciados permitem concluir que as mudanças da PNAB 2017 interferiram diretamente na atuação dos ACS. Apesar da pesquisa ter sido realizada justamente no período de transição na atualização da PNAB implantada em 2017, fica claro o impacto no âmbito da cobertura assistencial, sobretudo em relação ao objeto de trabalho do ACS.
40
Vianna, Carolina Avila, David Alejandro González e Alicia Matijasevich. "Utilização de ácido acetilsalicílico (AAS) na prevenção de doenças cardiovasculares: um estudo de base populacional". Cadernos de Saúde Pública 28, n. 6 (giugno 2012): 1122–32. http://dx.doi.org/10.1590/s0102-311x2012000600011.
Testo completoAbstract (sommario):
O objetivo foi estimar a prevalência de uso de ácido acetilsalicílico (AAS) na prevenção das doenças cardiovasculares (DCV). Estudo transversal de base populacional, realizado em Pelotas, Rio Grande do Sul, Brasil, em 2010. Dois desfechos foram considerados: uso de AAS na prevenção primária (indivíduos > 40 anos com pelo menos dois fatores de risco (hipertensão arterial sistêmica, diabetes mellitus e/ou dislipidemia) e uso de AAS na prevenção secundária (história de angina/infarto e/ou acidente vascular encefálico). Os desfechos foram analisados de acordo com variáveis demográficas, socioeconômicas e de estilo de vida. A prevalência de uso de AAS foi de 24,8% na prevenção primária e 34,3% na prevenção secundária. Na prevenção primária o uso de AAS foi maior nos indivíduos de cor não branca, maior faixa etária e com pior autopercepção de saúde. Na prevenção secundária, a prevalência de uso foi maior nos indivíduos com maior faixa etária, maior classe social e ex-fumantes. As prevalências de uso de AAS encontradas estão muito abaixo do recomendado para prevenção das DCV.
41
Tam, Constantine S., Hang Quach, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, Michael F. Leahy et al. "Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma". Blood Advances 4, n. 19 (6 ottobre 2020): 4802–11. http://dx.doi.org/10.1182/bloodadvances.2020002183.
Testo completoAbstract (sommario):
Abstract Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or relapsed/refractory (R/R) follicular lymphoma (FL). In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL/SLL (n = 45) and FL (n = 36). Common adverse events (AEs) included upper respiratory tract infection (51%; n = 23), neutropenia (44%; n = 20), contusion (33%; n = 15), cough, diarrhea, or fatigue (27%; n = 12 each), and pyrexia (22%; n = 10) in CLL/SLL patients and upper respiratory tract infection (39%; n = 14), contusion (28%; n = 10), fatigue (25%; n = 9), and cough (22%; n = 8) in FL patients. Neutropenia was the most common grade 3/4 AE (CLL/SLL, 31% [n = 14]; FL, 14% [n = 5]). Five patients required temporary dose reductions, and 5 discontinued the study drug because of AEs. Overall response rate (ORR) was 100% (n = 20) in treatment-naïve CLL patients and 92% (n = 23) in R/R CLL patients. ORR in 36 R/R FL patients was 72% (n = 26), with 14 complete and 12 partial responses. Median follow-up was 29 months (range, 8-37) for CLL patients and 20 months (range, 2-37) for FL patients. Zanubrutinib and obinutuzumab combination therapy was generally well tolerated. This trial was registered at www.clinicaltrials.gov as #NCT02569476.
42
Song, Jeonghoon. "Development of Active Front Wheel Steering(AFS) Controllers for SUV". Transaction of the Korean Society of Automotive Engineers 28, n. 9 (1 settembre 2020): 613–19. http://dx.doi.org/10.7467/ksae.2020.28.9.613.
Testo completo
43
Furman, Richard R., John C. Byrd, Roger G. Owen, Susan Mary O'Brien, Jennifer R. Brown, Peter Hillmen, Deborah Marie Stephens et al. "Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials." Journal of Clinical Oncology 38, n. 15_suppl (20 maggio 2020): 8064. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8064.
Testo completoAbstract (sommario):
8064 Background: Acala is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved in the US for patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and previously treated mantle cell lymphoma (MCL). We evaluated the safety profile of acala monotherapy (monotx) in multiple B cell malignancies. Methods: Data from pts with activated B-cell diffuse large B-cell lymphoma, CLL, follicular lymphoma, MCL, multiple myeloma, prolymphocytic leukemia, Richter syndrome, SLL, or Waldenström macroglobulinemia treated with ≥1 dose of acala monotx in 9 studies were pooled. Acala was administered at 100 mg BID in most pts (100–400 mg total dose daily). Adverse events (AE) were assessed. Results: A total of 1040 pts were included (median age: 67 y [range: 32–90]; ECOG status ≤1: 93%; median exposure duration: 24.6 mo [range: 0–58.5]). A total of 360 (34%) pts discontinued acala, most commonly due to progressive disease (PD; 17%). AEs led to acala discontinuation in 97 (9%) pts; those in > 2 pts were pneumonia (n = 5) and thrombocytopenia (n = 4). Incidence of AEs, including the most common (any grade and grade ≥3), are shown in the Table. Events of clinical interest (ECIs) included atrial fibrillation (afib) of any grade in 46 (4%) pts and grade ≥3 in 13 (1%) pts; major hemorrhage (any grade) in 37 (4%) pts; grade ≥3 infection in 183 (18%) pts; hypertension (any grade) in 79 (8%) pts and grade ≥3 in 36 (4%) pts; and second primary malignancies (SPM) excluding non-melanoma skin cancer (NMSC; any grade) in 68 (7%) pts. Median (range) time to first onset in days for each ECI (any grade) was: afib, 522 (8–1280); major hemorrhage, 293 (4–1327); infections, 92 (1–1317); hypertension, 157 (2–1345); SPM excluding NMSC, 339 (7–1499). Death was reported in 139 (13%) pts, most commonly due to PD (6%) and AEs (5%). Conclusions: Acala monotx has a favorable tolerability profile with increased exposure across multiple mature B cell malignancies. Additional analyses will further explore the longitudinal characteristics of AEs. [Table: see text]
44
Abe, Satomi, Hitoshi Nochi e Hiroshi Ito. "Human Articular Chondrocytes Induce Interleukin-2 Nonresponsiveness to Allogeneic Lymphocytes". CARTILAGE 8, n. 3 (2 agosto 2016): 300–306. http://dx.doi.org/10.1177/1947603516661820.
Testo completoAbstract (sommario):
Introduction We previously showed that articular chondrocytes (ACs) have immune privilege and immunomodulatory functions like those of mesenchymal stem cells. To elucidate these mechanisms, we focused on interleukin-2 (IL-2), which plays critical roles in lymphocyte mitogenic activity. The purpose of this study was to explore whether ACs affect the role of IL-2 underlying immunomodulatory functions. Material and Methods Irradiated human ACs from osteoarthritis donors were used. Third-party ACs were added to the mixed lymphocyte reaction (MLR) with or without recombinant human IL-2 (rhIL-2), and the levels of IL-2 and the soluble form of the IL-2 receptor α (sIL-2Rα) protein in supernatant were measured by enzyme-linked immunosorbent assay. Recombinant human IL-2 (rhIL-2) was also added to the MLR. To detect the expression of IL-2 receptor α (CD25) on lymphocytes in the MLR, flow cytometric analysis was performed. Last, ACs and allogeneic activated CD4+ T cell were co-cultured, and the expression of CD25 on activated T cells was examined by flow cytometry. Results Third-party ACs significantly inhibited the MLR and reduced the level of sIL-2Rα in a dose-dependent manner, but did not affect the concentration of IL-2. Exogenous rhIL-2 accelerated MLR but did not rescue the inhibitory effect of ACs. ACs inhibited the expression of CD25 on activated CD4+ T cells. Discussion Our results showed that third-party ACs inhibited the proliferation of allogeneic activated lymphocytes, thereby inhibiting production sIL-2Rα, although ACs did not affect IL-2 secretion from lymphocytes. Also, ACs inhibited CD25 expression on activated CD4+ T cells. Thus, ACs inhibited the immune response of allogeneic lymphocytes by inducing IL-2 nonresponsiveness.
45
葛, 建华. "Catalytic Oxidative DesulfurizationUsing[(CH3)NC16H33]4W10O32/H2O2/[Bmim]PF6System". Advances in Environmental Protection 04, n. 04 (2014): 112–22. http://dx.doi.org/10.12677/aep.2014.44016.
Testo completo
46
Galliano, Leony Morgana, e Felipe Fossati Reichert. "Intervindo em atividade física, alimentação e estresse em moradores de município de pequeno porte". Revista Brasileira de Atividade Física & Saúde 24 (2 aprile 2020): 1–7. http://dx.doi.org/10.12820/rbafs.24e0097.
Testo completoAbstract (sommario):
Objetivou-se apresentar o modelo conceitual e desafios de uma intervenção de educação em saúde, incluída por meio do Sistema Único de Saúde. Todos moradores de Dona Francisca, Rio Grande do Sul, de 50-80 anos de idade, atendidos pelos oito agentes comunitários de saúde (ACS) foram considerados elegíveis para a intervenção, que abrangeu: i) encontro individual; ii) contatos motivacionais; iii) encontros educacionais relacionados à atividade física, alimentação e controle de estresse. A intervenção foi conduzida pelos ACS previamente treinados. Foram realizadas três coletas de dados: i) linha de base (2014; n = 649); ii) intermediária (2015; n = 544) e; iii) final (2016; n = 555). Os principais desafios foram relacionados a pactuação dos ACS, baixa participação nos encontros educacionais e coleta de dados, especialmente em áreas rurais. Porém, houve capacitação dos ACS, maior acesso às informações de saúde para a população e coletas de dados que possibilitam traçar o perfil de uma população de município de pequeno porte.
47
Song, Ming-Fen, Li-Qiong Chen, Qiong-Yan Shao, Lin-Lin Hu, Wen-Juan Liu e Yong-Hua Zhang. "Efficacy and Safety of Jiawei Suanzaoren Decoction Combined with Lorazepam for Chronic Insomnia: A Parallel-Group Randomized Controlled Trial". Evidence-Based Complementary and Alternative Medicine 2020 (8 febbraio 2020): 1–8. http://dx.doi.org/10.1155/2020/3450989.
Testo completoAbstract (sommario):
Background. Chronic insomnia is a major public health problem, but there are limited effective therapies. Jiawei Suanzaoren Decoction (JW-SZRD) has been used as an alternative option for treating insomnia. This study aimed to investigate the long-term efficacy and safety of JW-SZRD in combination with lorazepam for chronic insomnia. Methods. A total of 207 participants were analyzed in this study. The treatment group (TG) received JW-SZRD and lorazepam orally, and the control group (CG) received lorazepam alone. The Insomnia Severity Index (ISI), the Self-Rating Depression Scale (SDS), the Self-Rating Anxiety Scale (SAS), and the Somatic Self-rating Scale (SSS) were evaluated at baseline, weeks 4, 8, and 12. The MOS 36-item Short Form Health Survey (SF-36) was assessed at baseline and week 12. Adverse effects (AEs) were evaluated by the Treatment Emergent Symptom Scale (TESS). Results. Both TG and CG showed obvious improvements in the sleep onset latency (SOL) (P=0.001 and 0.005) and total sleep time (TST) (P=0.0001 and 0.001). However, TG was more effective than CG at weeks 8 (P=0.02 for SOL, P=0.008 for TST) and 12 (P=0.03 for SOL, P=0.04 for TST), especially in shortening SOL (Cohen’s d = 1.28). The ISI reduction rate in TG was higher than that in CG at weeks 4, 8, and 12 (P=0.008, 0.001 and 0.001). After treatment, TG had lower SAS scores (P=0.0001, 0.007), less somatic symptoms (P<0.05 or 0.01), higher SF-36 scores (P<0.05 or 0.01), better compliance (P=0.0001), and less adverse effects (P<0.05 or 0.01) than those in CG. Conclusion. The combination of JW-SZRD with lorazepam can significantly improve sleep quality with fewer AEs. It is an effective treatment and superior to lorazepam alone for chronic insomnia.
48
Mei, Le Fu, Kai Ming Liang e Hai Bin Li. "The Effect of Zirconia Sol-Gel Coatings on Mild Steel Oxidation Resistance". Key Engineering Materials 280-283 (febbraio 2007): 1005–8. http://dx.doi.org/10.4028/www.scientific.net/kem.280-283.1005.
Testo completoAbstract (sommario):
The effect of zirconia coatings deposited by the sol-gel technique on the oxidation of mild steel was studied by scanning electron microscopy (SEM), X-ray diffraction (XRD) and measuring weight gain. It was found that the thickness of zirconia coatings is a crucial factor affecting the oxidation kinetics and the multilayer dip–coating is much more effective than the single coatings. Auger electron spectroscope (AES) was used to evaluate the depth composition of scale. The results suggest that the growth mechanism of the oxide scale for coated mild steel change from outward cation to inward anion diffusion, during oxidation.
49
Alaidi, Abdul Hadi M. "Enhanced a TCP security protocol by using optional fields in TCP header". Journal of Education College Wasit University 1, n. 24 (17 gennaio 2016): 485–502. http://dx.doi.org/10.31185/eduj.vol1.iss24.189.
Testo completoAbstract (sommario):
The Transfer Control Protocol (TCP) itself does not guarantee the security of data that it transmits. However, under some circumstances, the security of TCP communication is required, e.g. the client-server communication in banking systems. Nowadays, the source socket layer (SSL) protocol is widely used; however, SSL is based on RSA (a public-key cryptographic algorithm) algorithm, which would require more computational resource. Therefore, an alternative faster solution utilizing symmetrical algorithm (AES) are proposed to achieve these goals: bidirectional authentication, encrypted data transmission and Integrity check. Moreover, use the optional fields in TCP header for carrying related information and introduced a new device SAM (Secure access module) which provides security-related functionalities: encryption, decryption, key-diversification etc
50
Meyer, Oliver, James B. Bussel, Raymond S. Wong, Abderrahim Khelif, Miona Stankovic, Joan Maier e Mansoor N. Saleh. "Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study". Blood 132, Supplement 1 (29 novembre 2018): 1152. http://dx.doi.org/10.1182/blood-2018-99-114694.
Testo completoAbstract (sommario):
Abstract Background: ITP is an acquired autoimmune disorder. Second-line treatment options include EPAG, romiplostim (both stimulate platelet production), ritux (a monoclonal anti-CD20 antibody that causes temporary but complete depletion of peripheral B cells), splenectomy (spl), and other immunosuppressive agents. This subanalysis of EXTEND, a global, open-label, extension study, evaluated long-term EPAG in adults with ITP of ≥6 months' duration according to prior ritux use. Aims: Describe efficacy and safety of EPAG in ITP patients (pts) according to prior ritux use. Methods : In EXTEND (Wong et al. Blood 2017;130:2527-36), pts started EPAG at 50 mg/day, with dose adjusted as required to achieve platelet counts of 50-200x109/L. Results: Of 302 pts in EXTEND, 70 (23%) had previously received ritux. Of these pts, mean±SD age was 53±14 years (yrs), median (range) time since diagnosis was 71.3 (12-362) months, 67% were splenectomized, 61% were female, 76% had baseline platelet counts <30x109/L, 100% had received prior ITP therapy (66% received ≥5 prior therapies), and median (range) time since last ritux was 1.6 (52 days-5.1 yrs) yrs. Of 232 (77%) pts who had not received prior ritux, mean±SD age was 48±16 yrs, median (range) time since diagnosis was 51.6 (9-552) months, 29% were splenectomized, 68% were female, 68% had platelet counts <30x109/L, and 92% had received prior ITP treatment (13% received ≥5 prior therapies). Mean (range) EPAG daily dose was 53.4 (11-75) mg/day with prior ritux and 49.2 (1-75) mg/day with no prior ritux; median (range) exposure duration was 2.1 (2 days-6.3 yrs) yrs and 2.4 (14 days-8.7 yrs) yrs, respectively. For pts with and without prior ritux, platelet counts were ≥50x109/L without rescue therapy in 37% and 45% at week 1, 45% and 61% at week 2, 41% and 58% at week 4, and 54% and 63% at week 12, respectively; thereafter, the proportion with platelets ≥50x109/L without rescue therapy and median platelet counts were generally similar in both groups (Figure). Estimated median (95% CI) time to platelet counts ≥50 and ≥100x109/L, respectively, was 3.1 (2.1, 6.1) and 8.1 (3.3, 22.4) weeks with prior ritux, and 2.1 (2.0, 2.3) and 4.4 (3.1, 6.1) weeks with no prior ritux. Response to EPAG within the first 2 weeks of treatment seemed more likely in pts with >1.6 yrs since last ritux (n=23; 66%) than in those with ≤1.6 yrs since last ritux (n=14; 40%). Neither the number of previous ITP therapies nor spl status seemed to affect response to EPAG, irrespective of prior ritux. On-treatment adverse events (AEs) were reported in 68 (97%) and 209 (90%) pts with and without prior ritux, respectively: the most frequent were nasopharyngitis (36%, 21%), headache (33%, 27%), fatigue (29%, 13%), diarrhea (23%, 13%), arthralgia (21%, 13%), and upper respiratory tract infection (URTI; 20%, 24%). Grade 3 AEs occurred in 25 (36%) and 53 (23%) pts, most commonly pain in extremity (6%, <1%) and fatigue (4%, <1%). Serious AEs occurred in 22 (31%) and 74 (32%) pts, most frequently cataract (4%, 6%). The most common AEs considered related to EPAG were headache (13%, 9%), nausea (7%, 3%), fatigue (6%, 4%), cataract (4%, 5%) and increased alanine aminotransferase and aspartate aminotransferase (each 3%, 6%). Bleeding AEs were observed in 24 (34%) and 60 (26%) pts. Overall, incidence of AEs appeared unaffected by spl status. For pts with prior ritux, headache, URTI, pyrexia, and abdominal pain appeared to be more common in pts with <1 yr since last ritux dose, while influenza, epistaxis, rash, anemia, bronchitis and cataract appeared to be more frequent in pts with ≥1 yr since last dose (each ≥10% difference). Summary/conclusions: EPAG induced similar sustained on-treatment platelet increases in pts with and without prior ritux. While time since ritux did not appear to affect response to EPAG, the proportion of pts with platelet counts ≥50x109/L during the first 12 weeks was higher, albeit not significantly, in the no prior ritux group, despite both cohorts receiving similar EPAG doses. This may pertain to prior ritux pts having harder-to-treat disease (having received more prior ITP treatments, including spl); despite this, EPAG showed similar efficacy in both groups. Further study is required to better understand the higher incidence (≥10%) of the most commonly occurring (eg fatigue, nasopharyngitis and diarrhea) and of the Grade 3 AEs in the prior ritux group, as well as the increased frequency of certain AEs according to time since prior ritux. Disclosures Meyer: Amgen, Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Bussel:Uptodate: Honoraria; Rigel: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Momenta: Consultancy; Prophylix: Consultancy, Research Funding; Protalex: Consultancy; Amgen Inc.: Consultancy, Research Funding. Wong:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Stankovic:Novartis: Employment. Maier:Novartis: Employment.